IN RESPONSE: I am familiar with Dr. Sotos' work on the history of sleep apnea and cite it in my article and the manuscript of my book on the history of obesity (Levine DI. Managing Bodies in the Land of Plenty: Diet, Nutrition, and Obesity in the US. In preparation.). His questions about my article bring to light several of the most important and exciting challenges that historians face in attempting to illuminate the patient experience of any illness across the decades.
Because of a lack of exact machinery and common fluctuations in reporting, competing measurements of height and weight abound, especially for well-known public figures. Historians must choose which sources they deem most reliable. For my work on Taft, I chose to use corroborated reports of his contemporaries and early biographers (1) instead of sources that relied on self-reporting (such as notoriously inaccurate early data for life insurance purposes) (2) . Either approach may well be off the mark by a few inches or pounds, which is why obtaining exact biometric information on historical figures may be impossible. Fortunately, we do not need to know the exact height or weight of a historical figure to find meaning in weight loss patterns, shifting communication techniques between physician and patient, or disease-oriented approaches to obesity. This is the true gift of the historical letters exchanged between Taft and his physician.
Dr. Sotos is right to point out that the Library of Congress' collection of Taft's papers is immense and only loosely organized, but the index to that collection has 40 entries for correspondences sent from Yorke-Davies to Taft or high-ranking members of his White House between 1905 and 1914 (3) . Many other items in the collection reference Taft's treatment with Yorke-Davies and weight loss, such as Taft's letters to his family and friends. Not all of these entries are individual personal letters (some are dietary regimens, receipts, or short notes), but all are important evidence of the most extensive correspondence I have been able to find in years of research investigating communication between physician and patient for treatment of obesity during this period. Taft's records were saved for posterity precisely because of his elite political status, and the correspondence itself existed chiefly because he chose to pursue treatment with a physician living abroad, making this a unique collection, indeed.
Finally, one of the most important responsibilities of historians of medicine is to evaluate available archival materials in light of the many other sources detailing the relevant context of this information. In my article, I had space to recount only a few of the political and social responses to Taft's weight and weight loss efforts. In my forthcoming book, I am able to explore these aspects of Taft as a modern patient with obesity and a public figure in far more detail, as well as give a detailed analysis of the meanings behind points of departure between written and typed weight records. Still, the information included in my article, designed to be particularly of use to a clini-
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Letters cian audience, presents printed evidence and an editorial cartoon showing that Taft's weight and attempts at weight loss were of continuing and evolving interest to the press and the reading public.
Deborah I. Levine 
Triple Therapy for Hepatitis C Virus Infection in Patients Receiving Hemodialysis

TO THE EDITOR:
We read Liu and colleagues' article (1) with great interest. Cure of hepatitis C virus (HCV) infection is crucial in patients receiving hemodialysis who are awaiting a kidney transplant. Hepatitis C virus infection is associated with decreased survival before and after kidney transplantation (2) . However, interferon treatment after transplantation is contraindicated because of a high risk for acute rejection.
Liu and colleagues report results of a randomized trial comparing the efficacy and safety of pegylated interferon plus low-dose ribavirin with those of pegylated interferon monotherapy in 205 treatment-naive patients with HCV infection receiving hemodialysis. They concluded that the virologic response was greater with combination therapy than monotherapy. However, the rate of sustained virologic response with combination therapy was only 64%.
Protease inhibitors have significantly improved the viral response in patients with HCV genotype 1, but no data are available for patients with end-stage renal disease (3) . Recently, the pharmacokinetic properties of the protease inhibitor boceprevir were found to be similar in patients with end-stage renal disease and healthy control participants (4) . A recent study found early rapid viral response in 3 of 4 patients receiving hemodialysis after 12 weeks of triple therapy with pegylated interferon-␣2a, ribavirin, and telaprevir (5) .
At our center, we have started to administer triple therapy with protease inhibitors to patients receiving hemodialysis. Here, we describe the first case to our knowledge of HCV infection cured with triple therapy with pegylated interferon, ribavirin, and boceprevir in a candidate for kidney transplantation receiving hemodialysis.
A 49-year-old male candidate for kidney transplantation who had received hemodialysis for 17 years was referred because of chronic HCV genotype 1a (interleukin-28B CT genotype) in August 2011. A biopsy specimen of the liver showed advanced fibrosis. One year ago, he began receiving antiviral treatment with adapted doses for hemodialysis (pegylated interferon-␣2a, 180 mcg/wk, and ribavirin, 200 mg/d). This therapy was stopped because of breakthrough at month 5.
In October 2011, triple therapy with pegylated interferon-␣2a, ribavirin, and boceprevir (800 mg/8 h) was started. The baseline viral load was 537 030 IU/mL. Four weeks later, HCV RNA levels were undetectable. The triple therapy was continued for 9 months, followed by pegylated interferon and ribavirin until October 2012. Adverse effects were asthenia and grade 3 anemia, which required an increased dose of erythropoietin and transfusion of 1 unit of blood.
The patient achieved sustained virologic response 24 weeks after therapy was discontinued. He is now a candidate for kidney transplantation, and the HCV infection has been cured. Our positive results should encourage the use of such therapy for patients with end-stage renal disease, especially those with advanced fibrosis who are awaiting a kidney transplant. IN RESPONSE: Dr. Lemoinne and colleagues' patient had a low probability to achieve sustained virologic response from dual therapy because he was male and had advanced hepatic fibrosis and an unfavorable interleukin-28B genotype. A previous small-scale study reported that telaprevir-based triple therapy had higher sustained virologic response rates than dual therapy in treatment-naive patients with HCV genotype 1 receiving hemodialysis. However, those who received triple therapy had more hematologic toxicity, skin rash, and dysgeusia (1). Data on previously treated patients with HCV infection receiving hemodialysis are limited except for 1 study on those who relapsed after receiving pegylated or standard interferon-␣2a monotherapy (2) .
On the basis of Dr. Lemoinne and colleagues' case report, the efficacy and safety of triple therapy are fair to re-treat patients with HCV genotype 1 whose condition was resistant to previous dual therapy. General practicing physicians should be aware that patients receiving telaprevir-or boceprevir-based triple therapy, especially those receiving hemodialysis, have a higher risk for severe anemia than those receiving dual therapy (3). Furthermore, universal triple therapy would be cost-effective only if the least-expensive protease inhibitor is used for patients with advanced fibrosis (4) . Therefore, the value of telaprevir-or boceprevir-based triple therapy in this special clinical setting needs to be confirmed by larger studies.
Recently, the newer generation of direct-acting antiviral agents, either in interferon-containing or interferon-free regimens, have shown excellent safety and efficacy to treat patients with HCV infection. Nevertheless, the pharmacokinetic profiles of these novel agents in patients receiving hemodialysis remain scanty (5) . The optimized use of these agents in patients with HCV infection receiving hemodialysis awaits further well-designed clinical studies. 
Links Between Herpes Zoster Incidence and Childhood Varicella Vaccination
TO THE EDITOR: Hales and colleagues (1) found a 39% increase in herpes zoster (HZ) incidence in the United States between 1992 and 2010. They concluded that the annual increase in HZ incidence could not have been caused by the implementation of varicella vaccination but was already present before this vaccination was introduced in 1996. Although the study was well-performed, the validity of their final conclusion would benefit from further exploration of their interesting data set.
First, the lack of a difference in HZ incidence before and after introduction of varicella vaccination could be caused by a transitional phase during which registration practices improved. This means that during the start-up phase of electronic registration of International Classification of Diseases, Ninth Revision, Clinical Modification, codes, the incidence of some conditions could have been artificially increased (2). Therefore, it would be interesting to show and analyze the data in Appendix Figure 2 of the article beginning in 1992 rather than 1995.
Second, the efficacy of HZ vaccination (3) and, as the authors note, exposure to children decrease with age. In the current analysis, an actual effect of varicella vaccine implementation in relatively younger age groups could be missed because all persons older than 65 years were combined. The analysis would thus have benefitted from the addition of the variable "age group" to the interaction term between calendar year and implementation period.
Third, a major limitation is that the data set includes only persons older than 65 years. Indeed, modeling studies over the time span observed here predict that HZ incidence will increase most in those younger than 65 years (4, 5) .
Fourth, the interstate comparison of HZ incidence would benefit from using data on the incidence of natural and breakthrough varicella or infection estimates based on serial age-specific seroprevalence instead of 1-dose vaccination coverage in children younger than 36 months, especially because potentially influential catch-up vaccination in older children seems to have been ignored.
Finally, the authors do not expect a substantial effect of HZ vaccination in persons aged 60 years or older (in 2010, 14.4% of persons older than 60 years had received the vaccine). However, they seem not to have explored this factor in the analyses (for example, in relation to HZ incidence in immunocompetent persons).
In conclusion, several issues remain to be addressed before the data presented in this study can confirm that widespread varicella vaccination has no influence on HZ incidence in unvaccinated groups in the United States. 1980 (1) . Therefore, initial increases in HZ incidence during the first few years of our study cannot be an artifact of a start-up phase of a new system for recording claims data.
Benson Ogunjimi, MD, MPhys
Mixing with children does decrease in older age groups; however, mixing patterns do not vary substantially by age among adults older than 65 years (2) . Between 1992 and 2010, HZ incidence increased at a similar rate in all age groups and did not accelerate in any age group. To confirm this factor, we tested a 3-way interaction among calendar year, varicella vaccination implementation period, and age group in the Poisson model as Drs. Ogunjimi and Beutels suggest, but our findings were not statistically significant.
Drs. Ogunjimi and Beutels correctly note that the findings in our study apply only to adults older than 65 years and cannot exclude the possibility of an effect in younger age groups, which previous mathematical models have predicted. However, previous studies in the United States (3) and Canada (4) have not shown an acceleration in HZ incidence in adults younger than 65 years after implementation of childhood varicella vaccination programs.
Although few U.S. state health departments collected data on varicella incidence during the period of our study, Zhou and colleagues (5) used MarketScan databases to evaluate the effect of childhood varicella vaccination coverage on varicella incidence between 1994 and 2002 as reported by the National Immunization Survey. They found that decreases in varicella incidence were significantly greater and faster in those living in 11 states with consistently high varicella vaccination coverage than in those in 19 states with consistently low coverage. We and Leung and associates (3) subsequently found that rates of HZ did not differ in states with high and low varicella vaccination coverage.
The HZ vaccine was introduced in 2006 with 1.9% uptake in 2007 that increased to only 14.4% in 2010; we therefore expect the effect of the HZ vaccination, with 51% vaccine efficacy, on overall HZ incidence to be small. Results of an additional analysis limited to the period before introduction of the HZ vaccine (1992 to 2006) were essentially the same as those for the entire study period (1992 to 2010); implementation of the childhood varicella vaccination program did not lead to increases in HZ incidence compared with the period before introduction of the varicella vaccine.
In conclusion, we agree with Drs. Ogunjimi and Beutels that it is impossible to confirm from our study that widespread varicella vaccination does not influence HZ incidence in certain persons. However, although studies of the effect of exposure to varicella on individual risk for HZ have shown conflicting results, recent studies on the effect of decreasing childhood varicella incidence on adult HZ incidence provide reassurance that the varicella vaccination program has not resulted in population-level increases in HZ rates.
TO THE EDITOR:
As a long-practicing physician of a certain age, I wholeheartedly agree with Sinsky and Beasley's thoughtful essay about physician multitasking-namely, computer keyboarding and "mousing"-during the patient visit (1). It's distracting, impairs our observational skills, and is downright rude; it clearly negatively affects the quality of the encounter.
I can also personally attest that this behavior induces an unpleasantly fatiguing, hypervigilant state, making the workday resemble a slowly accelerating treadmill. The last patient of the day departs; it's dark outside; and I'm hungry, irritable, and tired. I want to go home. But now it's time to spend the next 2 or 3 hours communing with the electronic medical record (EMR) system to complete the always-plentiful unfinished business of the day.
The as-yet unacknowledged "big picture" of the state of primary care internal medicine today is the near-total domination of the clinical encounter-sometimes for better but, in my opinion, too often for worse-by the EMR. Meaningful use becomes less meaningful every day, at least for patient care. Is this meaningful progress? Unfortunately, the authors' solutions to the stated problems are but an expensive compensatory approach and do little to address the problem's root cause: Potentially helpful technology is forcing physicians to "serve the technology" rather than use it to "assist" them in improving the delivery of patient care.
The newer team-based care models require the hiring of everincreasing members, along with their associated costs. How many persons does it now take to "feed" the constantly expanding clinical encounter information into the EMR? For starters: nurses, physicians, medical assistants, "health coaches," scribes, and probably more as these systems "mature." It needs to be acknowledged that systems requiring such extensive human resources are by definition not well-designed. Solutions created primarily to compensate for these poorly designed systems will ultimately fail, as the current environment, awaiting the impending health care system tsunami referred to by the authors, becomes unsustainably stressed.
Technologically, the tail is wagging the dog. As the capacity to acquire, record, and store information increases, the currently designed electronic systems will reflexively generate more and more information to be stored. Care providers will never get ahead of the curve. Adding more employees and increasing practice overhead without any expectation or guarantee of additional reimbursement (translation: seeing more patients) in an already-constrained financial environment is not a responsible solution.
The honorable intent of the EMR, its prime directive, was to facilitate dispersion and availability of clinically useful patient information. That goal was co-opted by powerful interests in the health care industry (not physicians) that instead reprogrammed the EMR, empowering it to be the primary managing director of the present all-consuming documentation frenzy that is the real tsunami in the room! When I begin a visit, I apologize to my patients for not looking at them as I speak to the screen and type or mouse away. I refer to our EMR system as an all-powerful documenting, billing, and physician-grading device masquerading as an EMR. I quote to my patients my practice manager's simple and compelling charge to me when I complain: "If you wanna get paid," he says as he points to the screen, "this is what you gotta do."
I think that all of us, including the American College of Physicians, need to compensate less, open our eyes and minds, take and make a stand, and think bigger-a lot bigger-and better! Michael E. Miller, MD Boston University Affiliated Physicians Boston, Massachusetts IN RESPONSE: Dr. Pollak points to the importance of efficiency. We agree. We believe that clinical excellence depends on operational efficiency.
When myriad daily clerical tasks that previously took a few seconds now each take a few minutes, the time adds up and something has to give. We are concerned that what gives is often the clinical care of the patient and the work-life balance of the physician.
Dr. Pollak observes that EMRs have not optimally supported team-based care. At a time when our rhetoric and aspirations are moving toward teams, our technologies and policies are paradoxically pushing more work to the physician and are conceptualized around the physician alone in a room with a computer.
Although we support teams helping with patient care and record keeping, we believe that much waste could be eliminated by decreasing requirements for work that does not uniquely add value for the patient but instead consumes an ever-greater portion of the collective clinical effort. Prime among this waste is documentation, especially of the visit note, which is often composed on a billing template. Most visit notes will be read once-if at all-because of their lack of useful content and then sink down into the sedimentary layers of the record.
Dr. Miller mentions the "near-total domination of the clinical encounter" by the EMR and challenges us to think beyond survival strategies and workarounds and get to the root of the "documentation frenzy" problem. Again, we agree. Do we really need 6-page visit notes primarily made up of boilerplate or billing-centric text? Does every clinical act and thought need to pass through the EMR? Do the hundreds of electronic signatures and sign-offs required of a physician each day add enough value to justify the costs?
Most readers will relate to being tired and hungry and just wanting to go home yet facing several hours of clerical work before the day is done. And because, unlike many other workers, physicians are off the clock, these costs are invisible to health care leaders. Invisible, at least, until students turn away from primary care specialties and physicians walk away from their profession whispering, "I can't do this any longer."
The cry of the heart is manifest in high rates of physician burnout, particularly in primary care, and we believe that this burnout stems from the frequent mismatch of technology, policy, and implementation to the mission of medicine. As physicians, we know that we are spending our days doing the wrong work. We feel trapped at the sharp end of many well-intended technology and policy spears. Our collective challenge is to recognize the depths of the problem and bring our considerable energy and creativity to bear on its remedy.
Christine A. Sinsky 
